FULGENT GENETICS, INC. Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year
FULGENT GENETICS, INC. (FLGT) had Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year of $4.95 million as of 2026-06-30, per its 10-Q filed 2026-07-30.
Financial Statements › Notes › Goodwill and Other › Intangible Asset, Finite-Lived, and Capitalized Cost, Software to be Sold, Leased, or Marketed, Estimated Amortization Expense
us-gaap:FiniteLivedIntangibleAssetsAmortizationExpenseRemainderOfFiscalYear · last filed 2026-07-30
- 2026-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $4.95M.
- 2026-03-31: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $7.61M.
- 2025-09-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $2.02M.
- 2025-06-30: Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year $3.98M.
| Period end | Finite-Lived Intangible Asset, Expected Amortization, Remainder of Fiscal Year |
|---|---|
| 2026-06-30 | $4.95M 10-Q · filed 2026-07-30 |
| 2026-03-31 | $7.61M 10-Q · filed 2026-05-01 |
| 2025-09-30 | $2.02M 10-Q · filed 2025-11-07 |
| 2025-06-30 | $3.98M 10-Q · filed 2025-08-01 |
| 2025-03-31 | $5.97M 10-Q · filed 2025-05-02 |
| 2024-09-30 | $2.00M 10-Q · filed 2024-11-08 |
| 2024-06-30 | $3.98M 10-Q · filed 2024-08-02 |
| 2024-03-31 | $5.97M 10-Q · filed 2024-05-03 |
| 2023-09-30 | $1.96M 10-Q · filed 2023-11-03 |
| 2023-06-30 | $3.91M 10-Q · filed 2023-08-04 |
| 2023-03-31 | $5.90M 10-Q · filed 2023-05-05 |
| 2022-09-30 | $1.96M 10-Q · filed 2022-11-07 |
| 2022-06-30 | $3.96M 10-Q · filed 2022-08-04 |
| 2022-03-31 | $2.71M 10-Q · filed 2022-05-05 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| BIODESIX INC (BDSX) | United States | $0.312B | |
| Lumexa Imaging Holdings, Inc. (LMRI) | United States | $0.951B | |
| EXAGEN INC. (XGN) | United States | $0.212B | -5.95 |
| Freenome, Inc. (FRNM) | United States | $0.143B | |
| CASTLE BIOSCIENCES INC (CSTL) | United States | $1.074B | -37.45 |
| SERA PROGNOSTICS, INC. (SERA) | United States | $0.062B | -5.75 |
| AMERICAN SHARED HOSPITAL SERVICES (AMS) | United States | $0.010B | -5.64 |
| Advanced Biomed Inc. (ADVB) | $0.009B | ||
| Aclarion, Inc. (ACON) | United States | $0.008B | |
| BioNexus Gene Lab Corp (BGLC) | $0.004B |